Microscan panel

Manufactured by Beckman Coulter

Sourced in United States

The MicroScan Panels are a series of laboratory test panels designed to identify and determine the antimicrobial susceptibility of a wide range of microorganisms, including bacteria and yeast. These panels utilize automated and manual testing methods to provide accurate and reliable results for clinical microbiology laboratories.

Automatically generated - may contain errors

Lab products found in correlation

Vitek 2, by bioMérieux (1 mentions) Walkaway system, by Beckman Coulter (1 mentions) Lightmix modular carbapenemase kits, by TIB Molbiol (1 mentions) Lightcycler 480 instrument 2, by Roche (1 mentions) Microscan walkaway system, by Beckman Coulter (1 mentions)

5 protocols using microscan panel

Antibiotic-Resistant GNR Prevalence Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Clinical information extracted from the database included patient age, sex, residence in nursing home, antibiotic use within the last three months, hospital admission within the last three months, history of isolation of resistant GNR within the last six months, bed-ridden status (unable to get off the bed without assistance), comorbidities (including diabetes mellitus, malignancy, and immunodeficiency), and placement of a long-term urinary catheter before admission.
The automated Vitek 2 (bioMerieux) method was used for bacterial identification and antimicrobial susceptibility testing of GNRs. Susceptibility test results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) breakpoints [16 ]. The third-generation cephalosporin used for susceptibility testing was changed from ceftriaxone to cefotaxime in our hospital during the study period. Therefore, we have presented the susceptibility results for cefotaxime instead of ceftriaxone throughout this manuscript. The ESBL confirmation tests were performed using the MicroScan Panel (Beckman Coulter). When multiple GNRs were isolated from a single patient, we regarded the patient as being in the resistant GNR group if at least one GNR was resistant to ceftriaxone.

Kanda N., Hashimoto H., Sonoo T., Naraba H., Takahashi Y., Nakamura K, & Hatakeyama S. (2020). Gram-negative Organisms from Patients with Community-Acquired Urinary Tract Infections and Associated Risk Factors for Antimicrobial Resistance: A Single-Center Retrospective Observational Study in Japan. Antibiotics, 9(8), 438.

+ Open protocol

+ Expand

Antibiotic Susceptibility Testing of Respiratory Pathogens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Nasopharyngeal swabs were obtained by trained staff from all patients immediately upon admission. Aerobic culture was performed using blood agar medium and mannitol salt medium; 5%-6% carbon dioxide gas cultures were performed using chocolate medium. Drug susceptibility analysis was performed by using a microliquid dilution method with a microscan panel (Beckman Coulter, Brea, CA, USA) that complied with the 2012 criteria of the Clinical and Laboratory Standards Institute. In accordance with these criteria, S. pneumoniae with a minimum inhibitory concentration (MIC) for penicillin of ≤0.06 μg/ml, 0.12-1.0 μg/ml, or ≥2.0 μg/ml was defined as penicillin-susceptible S. pneumoniae (PSSP), penicillin-intermediately resistant S. pneumoniae (PISP), or penicillin-resistant S. pneumoniae (PRSP). H. influenzae was categorized in accordance with the combined results of a β-lactamase production test and the MIC for ampicillin (ABPC). β-lactamase-nonproducing, ABPC-susceptible H. influenzae (BLNAS) isolates had an ABPC MIC of <4 μg/ml; β-lactamase-nonproducing, ABPC-resistant H. influenzae (BLNAR) isolates had an ABPC MIC of ≥4 μg/ml; and β-lactamase producing, ABPC-resistant H. influenzae (BLPAR) isolates had an ABPC MIC of ≥4 μg/ml. S. aureus with an MIC of ≥4 μg/ml for oxacillin was defined as methicillin-resistant S. aureus (MRSA).

Takeyama A., Suzuki K., Ito M., Sato M., Hashimoto K., Katayose M, & Hosoya M. (2021). Clinical course and background of nasopharyngeal antibiotic-resistant bacteria carriers among preschool children hospitalized for lower respiratory tract infection. Fukushima Journal of Medical Science, 67(3), 143-149.

+ Open protocol

+ Expand

Antimicrobial Susceptibility Testing of Staphylococcus aureus

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antimicrobial susceptibility testing was conducted using the DxM MicroScan WalkAway ID/AST system. The antibiotics tested included: FOX (cefoxitin), OXA (oxacillin), ERY (erythromycin), CLI (clindamycin), CIP (ciprofloxacin), TET (tetracycline), GEN (gentamicin), RIF (rifampicin), SXT (sulfamethoxazole/trimethoprim), QD (quinupristin-dalfopristin), DAP (daptomycin), LNZ (linezolid), and VAN (vancomycin). Antibiotic MIC results were tested using MicroScan Panels (Beckman Coulter, Inc., Calif., United States). The resistance criteria were based on the Clinical and Laboratory Standards Institute (CLSI) 2021 guidelines (CLSI, 2021 ). Staphylococcus aureus ATCC 29213 was used as standard bacterial strain.

Huang L., Zhu L., Yan J., Lin Y., Ding D., He L., Li Y., Ying Y., Shen L., Jiang Y., Cai H, & Jiang T. (2024). Genomic characterization and outbreak investigations of methicillin-resistant Staphylococcus aureus in a county-level hospital in China. Frontiers in Microbiology, 15, 1387855.

+ Open protocol

+ Expand

Urine Culture and Antibiotic Susceptibility

Check if the same lab product or an alternative is used in the 5 most similar protocols

Urine cultures were performed as part of clinical routine following standard laboratory procedures. Cultures with growth yielding ≥10⁵ colony-forming units/mL of a single bacterial type in a urine sample collected midstream were considered positive. Pyuria was defined as ≥10 white blood cells/mm³. Only one urine culture per patient was included.
Antibiotic susceptibility testing was performed by microdilution using MicroScan panels (Beckman Coulter, Brea, CA, USA) in an automated WalkAway system (Beckman Coulter). Results were interpreted following European Committee for Antimicrobial Susceptibility Testing (EUCAST) 2019 guidelines [8 ]. Isolates with AMC minimum inhibitory concentration (MIC) values >8 mg/L were considered resistant. Phenotypic detection of ESBLs and carbapenemases was in accordance with EUCAST recommendations [33 ]. Molecular confirmation of carbapenemases was by real time PCR, using LightMix^® modular carbapenemase kits (TIB Molbiol, Berlin, Germany) in a LightCycler 480 II instrument (Roche Diagnostics, Rotkreuz, Switzerland).

Martínez-Casanova J., Gómez-Zorrilla S., Prim N., Dal Molin A., Echeverría-Esnal D., Gracia-Arnillas M.P., Sendra E., Güerri-Fernández R., Durán-Jordà X., Padilla E., Horcajada J.P, & Grau S. (2021). Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by Escherichia coli or Klebsiella pneumoniae: The Role of Prior Exposure to Fluoroquinolones. Antibiotics, 10(5), 582.

+ Open protocol

+ Expand

Antibiotic Susceptibility of P. aeruginosa

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bacterial isolates were identified as P. aeruginosa following standard procedures. Antibiotic susceptibility testing of isolates was performed by broth microdilution using MicroScan® panels [Beckman-Coulter] in the automated MicroScan® WalkAway system [Beckman-Coulter]. The following antimicrobials were tested: ciprofloxacin, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, aztreonam, gentamicin, tobramycin, amikacin, and colistin. Ceftolozane-tazobactam was not in routine use for a large part of the study; it was tested by Etest® gradient diffusion (bioMérieux, Marcy-l'Etoile, France) from 2017 onwards. Antibiotic susceptibility testing results were categorized according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria [25 ] in force at the time of urine culture.

López Montesinos I., Gómez-Zorrilla S., Palacios-Baena Z.R., Prim N., Echeverria-Esnal D., Gracia M.P., Montero M.M., Durán-Jordà X., Sendra E., Sorli L., Guerri-Fernandez R., Padilla E., Grau S, & Horcajada J.P. (2021). Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study. Infectious Diseases and Therapy, 11(1), 335-350.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!